Conix

Cambridge Consultants is well known for the design and development of next generation products for clients around the world.  However, alongside this activity, we also regularly invest time in creating exciting IP that will help clients gain competitive advantage.  One example of this IP development was the creation of ‘Conix’. 

Conix is a high performance ‘reverse flow cyclone’ inhaler technology for the delivery of dry powders to the lung.  Whilst the Conix platform technology is simple in its design, its true strength lies in an ability to deliver drug effectively to the deep lung whilst at the same time reducing upper airway deposition.  The technology is based around a novel 'reverse flow cyclone' and contains no moving parts or propellants.  The unique swirling action within the patented cyclone provides a highly effective deagglomeration process, enabling a large percentage of drug to be delivered efficiently into the lung.  This action also overcomes the problem that many inhalers have, where the drug is released within just a fraction of a second, before the patient has had time to reach their optimal inhalation rate.  The cyclone distributes the drug throughout the inhalation manoeuvre, enabling better use of the patient’s lung power, even where this is limited.  The Conix technology has demonstrated up to 40% increases in respirable dose compared to market leading products in back-to-back trials.

We successfully licensed this technology to 3M Drug Delivery Systems in December 2008 in an exclusive technology license and purchase agreement. 

Conix is just one example of how we have helped the drug delivery industry move forward with innovation.  You can find more information about other Medical Technology IP here.